Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages

BACKGROUND: Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its immunomodulatory effects, besides anti-angiogenesis, were not clearly defined. METHODS: In vivo antitumor efficacy was tested...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Da-Liang, Chen, Chia-Wei, Hsu, Chia-Lang, Chung, Chih-Hung, Feng, Zi-Rui, Lee, Bin-Shyun, Cheng, Ann-Lii, Yang, Muh-Hwa, Hsu, Chiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986673/
https://www.ncbi.nlm.nih.gov/pubmed/33753566
http://dx.doi.org/10.1136/jitc-2020-001657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986673/
https://www.ncbi.nlm.nih.gov/pubmed/33753566
http://dx.doi.org/10.1136/jitc-2020-001657

Ejemplares similares